Health Care [ 9/12 ] | Pharmaceuticals [ 62/76 ]
NASDAQ | Common Stock
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases.
It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection.
It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections.
Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections.
The company is headquartered in Bothell, Washington.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 24 | -0.53 Decreased by -29.27% | -0.48 Decreased by -10.42% |
| May 13, 24 | -0.39 Increased by +39.06% | -0.54 Increased by +27.78% |
| Mar 28, 24 | -0.44 Increased by +20.00% | -0.60 Increased by +26.67% |
| Nov 13, 23 | -0.41 Increased by +41.43% | -0.53 Increased by +22.64% |
| Aug 14, 23 | -0.41 Increased by +86.33% | -0.58 Increased by +29.31% |
| May 15, 23 | -0.64 Decreased by -33.33% | -0.67 Increased by +4.48% |
| Mar 29, 23 | -0.55 Decreased by -14.58% | -0.73 Increased by +24.66% |
| Nov 14, 22 | -0.70 Decreased by -45.83% | -0.48 Decreased by -45.83% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -5.34 M Decreased by -28.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.96 M Increased by +24.89% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 144.00 K Increased by +N/A% | -4.46 M Increased by +0.87% | Decreased by -3.10 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -4.17 M Increased by +27.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.17 M Increased by +90.77% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.27 M Decreased by -25.08% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by -100.00% | -4.50 M Decreased by -22.20% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -5.71 M Decreased by -44.79% | Decreased by N/A% Decreased by N/A% |